Newsbenzinga
GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership
· Published
Article summary
GSK-backed Ris-Rez posts positive Phase 3 survival data in small-cell lung cancer as the company moves to end its collaboration with Alector.
An excerpt from the original article.
Comments —
Loading comments…